GENFIT S.A. (GNFT) News

GENFIT S.A. (GNFT): $4.53

-0.10 (-2.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GNFT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Filter GNFT News Items

GNFT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GNFT News From Around the Web

Below are the latest news stories about Genfit SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.

GENFIT appoints Jean-François Tiné to the Board of Directors

Lille, France; Cambridge, MA; March 04, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the appointment of Jean-François Tiné as an independent board member. GENFIT’s Board of Directors has appointed Jean-François Tiné to replace Philippe Moons who resigned from his position as member of the Board. Jean-François Tiné will also join the Strategy and Alliances Committee and Eric Baclet will become a member of the Audit Committee. Jean-François Tiné is a seasoned senior investment banking executive. In 2017, he was appointed Chairman of Equity Capital Markets at Natixis Corporate & Investment Banking after joining Natixis in 2005 as Global Head of Equity Capital...

Yahoo | March 4, 2021

Indus Announces Launch of Public Offering of 1,750,000 Shares of Common Stock

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) today announced that it has commenced an offering of 1,750,000 shares of common stock. The Company also plans to grant the underwriters a 30-day option to purchase up to 262,500 additional shares of common stock. INDUS intends to use the net proceeds from the offering to finance its development pipeline and acquisitions and for other corporate purposes. Morgan Stanley and Citigroup are acting as co-lead joint book-running managers for the proposed offering. Baird is acting as bookrunner and BTIG, JMP Securities and J.P. Morgan are acting as co-managers for the proposed offering. The proposed offering is being made pursuant to an effective shelf registration statement on Form S...

Yahoo | March 1, 2021

GENFIT: Revenues and Cash Position as of December 31, 2020

Cash and cash equivalents totaled €171 million as of December 31, 2020The announced cash position omits the partial buyback of the OCEANEs convertible bonds by GENFIT, for €47.48 million1, completed in January 2021 Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its cash position as of December 31, 2020 and revenues for 20202. Financials As of December 31, 2020, the Company’s cash and cash equivalents amounted to €171.0 million compared with €276.7 million, as of December 31, 2019. As of June 30, 2020, cash and cash equivalents amounted to €225.7 million. The cash position as of December 31, 2020 omits the cost of th...

Yahoo | February 26, 2021

INDUS Announces Fiscal 2020 Fourth Quarter and Fiscal 2020 Results

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) today reported financial results for the three months ended November 30, 2020 (the “2020 fourth quarter”) and the twelve months ended November 30, 2020 (“fiscal 2020”). 2020 Fourth Quarter & Recent Highlights Net Loss of ($11.1) million and ($12.7) million for the 2020 fourth quarter and fiscal 2020, respectively, an increase of 328% in net loss compared to the three months ended November 30, 2019 (the “2019 fourth quarter”) and a decrease of 447% from net income during the twelve months ended November 30, 2019 (“fiscal 2019”)Net Operating Income (“NOI”)* of $7.1 million and $26.9 million for the 2020 fourth quarter and fiscal 2020, respectively (respective increases of 12.6% a...

Yahoo | February 18, 2021

INDUS Announces Fiscal 2020 Fourth Quarter and Full Year Earnings Webcast

NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) announced today that it will host a pre-recorded webcast on February 19, 2021 at 8:00 A.M. Eastern Time to report on its financial results for the three months ended November 30, 2020 (“2020 fourth quarter”) and the twelve months ended November 30, 2020 (“fiscal 2020”). Supplemental materials containing additional financial and operating information will be available on INDUS’s website at the start of the webcast. All investors and other interested parties are invited to dial in to the listen-only webcast which, together with the supplemental information, can be accessed via the Investors section of INDUS’s website at www.indusrt.com/investors or the webcast can be accessed dir...

Yahoo | February 12, 2021

Genfit Pops 29% Pre-Market On ‘Positive’ Data From Liver Disease Therapy Study

Shares in Genfit popped 29% in pre-market trading on Wednesday after the late-stage biopharma company announced “positive” results from the Phase 2 clinical trial testing its elafibranor therapy in patients with Primary Biliary Cholangitis (PBC), a form of liver disease. Genfit (GNFT), which develops therapies for metabolic and liver diseases, said that the results from the Phase 2 trial of elafibranor showed a clinically relevant improvement on the primary and composite biochemical endpoints and a positive trend on pruritus improvement. At the same time, the therapy had a favorable tolerability profile.

Sharon Wrobel on TipRanks | February 10, 2021

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA

Yahoo | January 13, 2021

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

Lille, France; Cambridge, MA; January 13, 2021 \- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders’ extraordinary general meeting to be held on second notice on Monday, January  25, 2021, at 2:30 p.m. (Paris time) (the “Extraordinary General Meeting”) and informs holders of its bonds convertible into new shares and/or exchangeable for existing shares issued by the Company on October 16, 2017 (the “OCEANEs”) of certain changes in certain of the participation and organization procedures for the meeting of the holders of ...

Yahoo | January 13, 2021

January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening

* Partial buyback and amendment of the bond terms approved by approx. 98% of voting shareholders at this time * Insufficient quorum of 20.63% on first convening, but greater than the 20% quorum required on second convening * Extraordinary Shareholders Meeting will be reconvened on January 25, 2021 with the same agenda * Votes cast on the first convening remain valid for the second convening * Shareholder engagement remains important to ensure the success of this transaction, which aims to decrease the bond debt by nearly half and extend its maturity by 3 years.Lille, France; Cambridge, MA; January 12, 2021 \- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced tha...

Yahoo | January 12, 2021

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; January 11, 2021 \- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2020: * 88,929 shares * €687 988.75During the second half of 2020, total trading was: * On the buy side: 1,525,427 shares for a total amount of €6,221,316.16 * On the sell side: 1,484,196 shares for a total amount of €6,066,211.46During this same period, the number of trades were: * On the buy side: 2,623 * On the sell side: 2,...

Yahoo | January 11, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0672 seconds.